Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-part phase 3 study of ZX008 in children and adults with Lennox-Gastaut syndrome
MOH_2018-10-08_002334Phase 3Not yet recruiting
- Sponsor
- Zogenix, Inc.
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in Lennox-Gastaut syndrome (LGS) (4 arms), sponsored by Zogenix, Inc. Primary endpoint: Change in frequency of drop seizures during titration plus maintenance. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
fenfluramine
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on MOH_2018-10-08_002334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-08_002334.